These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

262 related items for PubMed ID: 25155986

  • 21. Development of benzo[d]oxazol-2(3H)-ones derivatives as novel inhibitors of Mycobacterium tuberculosis InhA.
    Pedgaonkar GS, Sridevi JP, Jeankumar VU, Saxena S, Devi PB, Renuka J, Yogeeswari P, Sriram D.
    Bioorg Med Chem; 2014 Nov 01; 22(21):6134-45. PubMed ID: 25282650
    [Abstract] [Full Text] [Related]

  • 22. A high-throughput screen against pantothenate synthetase (PanC) identifies 3-biphenyl-4-cyanopyrrole-2-carboxylic acids as a new class of inhibitor with activity against Mycobacterium tuberculosis.
    Kumar A, Casey A, Odingo J, Kesicki EA, Abrahams G, Vieth M, Masquelin T, Mizrahi V, Hipskind PA, Sherman DR, Parish T.
    PLoS One; 2013 Nov 01; 8(11):e72786. PubMed ID: 24244263
    [Abstract] [Full Text] [Related]

  • 23. Design, synthesis, and evaluation of substituted nicotinamide adenine dinucleotide (NAD+) synthetase inhibitors as potential antitubercular agents.
    Wang X, Ahn YM, Lentscher AG, Lister JS, Brothers RC, Kneen MM, Gerratana B, Boshoff HI, Dowd CS.
    Bioorg Med Chem Lett; 2017 Sep 15; 27(18):4426-4430. PubMed ID: 28827112
    [Abstract] [Full Text] [Related]

  • 24. Novel peptidomimetic peptide deformylase (PDF) inhibitors of Mycobacterium tuberculosis.
    Gokhale KM, Telvekar VN.
    Chem Biol Drug Des; 2021 Jan 15; 97(1):148-156. PubMed ID: 32745362
    [Abstract] [Full Text] [Related]

  • 25. Fragment Discovery for the Design of Nitrogen Heterocycles as Mycobacterium tuberculosis Dihydrofolate Reductase Inhibitors.
    Shelke RU, Degani MS, Raju A, Ray MK, Rajan MG.
    Arch Pharm (Weinheim); 2016 Aug 15; 349(8):602-13. PubMed ID: 27320965
    [Abstract] [Full Text] [Related]

  • 26. High-throughput screen identifies small molecule inhibitors targeting acetyltransferase activity of Mycobacterium tuberculosis GlmU.
    Rani C, Mehra R, Sharma R, Chib R, Wazir P, Nargotra A, Khan IA.
    Tuberculosis (Edinb); 2015 Dec 15; 95(6):664-677. PubMed ID: 26318557
    [Abstract] [Full Text] [Related]

  • 27. Design and Development of Mycobacterium tuberculosis Lysine ɛ-Aminotransferase Inhibitors for Latent Tuberculosis Infection.
    Parthiban BD, Saxena S, Chandran M, Jonnalagadda PS, Yadav R, Srilakshmi RR, Perumal Y, Dharmarajan S.
    Chem Biol Drug Des; 2016 Feb 15; 87(2):265-74. PubMed ID: 26348876
    [Abstract] [Full Text] [Related]

  • 28. Discovery of novel acetohydroxyacid synthase inhibitors as active agents against Mycobacterium tuberculosis by virtual screening and bioassay.
    Wang D, Zhu X, Cui C, Dong M, Jiang H, Li Z, Liu Z, Zhu W, Wang JG.
    J Chem Inf Model; 2013 Feb 25; 53(2):343-53. PubMed ID: 23316686
    [Abstract] [Full Text] [Related]

  • 29. Rational drug design, synthesis and biological evaluation of dihydrofolate reductase inhibitors as antituberculosis agents.
    Tawari NR, Bag S, Raju A, Lele AC, Bairwa R, Ray MK, Rajan MG, Nawale LU, Sarkar D, Degani MS.
    Future Med Chem; 2015 Feb 25; 7(8):979-88. PubMed ID: 26062396
    [Abstract] [Full Text] [Related]

  • 30. Structural comparison of Mtb-DHFR and h-DHFR for design, synthesis and evaluation of selective non-pteridine analogues as antitubercular agents.
    Sharma K, Tanwar O, Sharma S, Ali S, Alam MM, Zaman MS, Akhter M.
    Bioorg Chem; 2018 Oct 25; 80():319-333. PubMed ID: 29986181
    [Abstract] [Full Text] [Related]

  • 31. Highly Potent and Selective N-Aryl Oxamic Acid-Based Inhibitors for Mycobacterium tuberculosis Protein Tyrosine Phosphatase B.
    Ruddraraju KV, Aggarwal D, Niu C, Baker EA, Zhang RY, Wu L, Zhang ZY.
    J Med Chem; 2020 Sep 10; 63(17):9212-9227. PubMed ID: 32787087
    [Abstract] [Full Text] [Related]

  • 32. Design and synthesis of 11α-substituted bile acid derivatives as potential anti-tuberculosis agents.
    Pore VS, Divse JM, Charolkar CR, Nawale LU, Khedkar VM, Sarkar D.
    Bioorg Med Chem Lett; 2015 Oct 01; 25(19):4185-90. PubMed ID: 26299346
    [Abstract] [Full Text] [Related]

  • 33. Discovery of novel inhibitors of Mycobacterium tuberculosis MurG: homology modelling, structure based pharmacophore, molecular docking, and molecular dynamics simulations.
    Saxena S, Abdullah M, Sriram D, Guruprasad L.
    J Biomol Struct Dyn; 2018 Sep 01; 36(12):3184-3198. PubMed ID: 28948866
    [Abstract] [Full Text] [Related]

  • 34. Development of potent chemical antituberculosis agents targeting Mycobacterium tuberculosis acetohydroxyacid synthase.
    Jung IP, Ha NR, Lee SC, Ryoo SW, Yoon MY.
    Int J Antimicrob Agents; 2016 Sep 01; 48(3):247-58. PubMed ID: 27451857
    [Abstract] [Full Text] [Related]

  • 35. Thiazole-aminopiperidine hybrid analogues: design and synthesis of novel Mycobacterium tuberculosis GyrB inhibitors.
    Jeankumar VU, Renuka J, Santosh P, Soni V, Sridevi JP, Suryadevara P, Yogeeswari P, Sriram D.
    Eur J Med Chem; 2013 Sep 01; 70():143-53. PubMed ID: 24148991
    [Abstract] [Full Text] [Related]

  • 36. Repurposing the chemical scaffold of the anti-arthritic drug Lobenzarit to target tryptophan biosynthesis in Mycobacterium tuberculosis.
    Evans GL, Gamage SA, Bulloch EM, Baker EN, Denny WA, Lott JS.
    Chembiochem; 2014 Apr 14; 15(6):852-64. PubMed ID: 24623674
    [Abstract] [Full Text] [Related]

  • 37. Design, Synthesis, and in vitro antitubercular activity of 1,2,3-triazolyl-dihydroquinoline derivatives.
    Banu S, Bollu R, Nagarapu L, Nanubolu JB, Yogeswari P, Sriram D, Gunda SK, Vardhan D.
    Chem Biol Drug Des; 2018 Jul 14; 92(1):1315-1323. PubMed ID: 29624868
    [Abstract] [Full Text] [Related]

  • 38. Synthesis, biological evaluation and molecular docking study of some novel indole and pyridine based 1,3,4-oxadiazole derivatives as potential antitubercular agents.
    Desai NC, Somani H, Trivedi A, Bhatt K, Nawale L, Khedkar VM, Jha PC, Sarkar D.
    Bioorg Med Chem Lett; 2016 Apr 01; 26(7):1776-83. PubMed ID: 26920799
    [Abstract] [Full Text] [Related]

  • 39. Mycobacterium tuberculosis lysine-ɛ-aminotransferase a potential target in dormancy: Benzothiazole based inhibitors.
    Reshma RS, Jeankumar VU, Kapoor N, Saxena S, Bobesh KA, Vachaspathy AR, Kolattukudy PE, Sriram D.
    Bioorg Med Chem; 2017 May 15; 25(10):2761-2771. PubMed ID: 28389113
    [Abstract] [Full Text] [Related]

  • 40. Toward antituberculosis drugs: in silico screening of synthetic compounds against Mycobacterium tuberculosisl,d-transpeptidase 2.
    Billones JB, Carrillo MC, Organo VG, Macalino SJ, Sy JB, Emnacen IA, Clavio NA, Concepcion GP.
    Drug Des Devel Ther; 2016 May 15; 10():1147-57. PubMed ID: 27042006
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.